Orchestra BioMed Holdings, Inc.OBIO

Orchestra BioMed Holdings, Inc. is a biomedical innovation outfit chasing large unmet needs in procedure-based medicine, but its most recent quarterly filing reads like a clinic in need of a turnaround. Revenue in the three months to March 2026 fell 19% year-over-year to $110,000, while operating losses widened to $22.1 million and cash burn hit $22.2 million. The company’s cash position stood at $28.4 million at 31 March 2026, giving it roughly 13 months of runway at the current pace. Behind the glossy pipeline graphics on its website sits a balance sheet where liabilities of $49.7 million outweigh assets of $100.7 million, and the only concrete number in the inventory line is $277,000-less than the cost of a single late-stage clinical trial.

The company’s marquee promise is the AVIM-enabled device, with revenue per unit notionally ranging between $500 and $1,600 depending on geography and formula. Yet the 10-Q shows product revenue at $110,000, down from $136,000 in the same quarter last year. The board’s 2022 licensing pact with Medtronic holds out the prospect of future partnership revenues, but today the revenue line is a flicker. Meanwhile, FDA filing trail for an IDE amendment to restart the Virtue SAB trial in coronary in-stent restenosis sits on file, waiting for the operational engine to catch up. The company’s manufacturing partner, however, can boast a greater than 99% on-time delivery rate, which is a metric that matters more when devices are actually shipping.

Orchestra BioMed was formed in 2018 by assembling a pipeline of multiple late-stage clinical candidates. The 10-K describes a company built to bring medical innovations to life, yet the latest 10-Q reports $110,000 in revenue, $22.1 million in operating losses, $22.2 million in cash burn from operations, and $184,000 spent on capex-mostly on the machinery needed to make nothing, yet. Diluted EPS for the quarter came in at a loss of $0.33 on 62.7 million shares outstanding, a per-share loss that is easier to compute than the path to profitability. The company’s inventory is a rounding error at $277,000, a detail that underscores how far removed the platform narrative is from the balance sheet reality.

For a deeper look at the filing mechanics, the SEC’s EDGAR index for Orchestra BioMed Holdings, Inc. (CIK 1814114) collects all submissions in one place, while the companyfacts JSON exposes the raw XBRL data underpinning the filings. Readers seeking the official narrative can start with the product pipeline page, which showcases the company’s late-stage pipeline graphics and device concepts. Neither the pipeline page nor the company website, however, changes the fact that the most recent filed revenue is $110,000.

What changed this week: the company filed routine exhibits under Rule 4 and Rule 144, mostly procedural filing trail that does not alter the financial picture. The evidence we have parsed does not include any new product revenue, approval, or launch since the last 10-Q. The tension, therefore, remains between the promise embedded in the Medtronic licensing agreement and the thin, declining revenue line in the 10-Q. The next catalyst that would materially shift the file is a signed commercial contract or a revenue-bearing product launch; neither appears in the current evidence set.